Mitsunobu Kitamura

Mitsunobu Kitamura

Auto-generated profile, based on publicly available information

Mitsunobu Kitamura

Sakakibara Heart Institute

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 January 2022 in Circulation
Verified
Journal Article
Closed access
PDF file
MMohamed Abdel Wahab.
Mohamed Abdel Wahab.
PHPhilipp Hartung
Philipp Hartung
ODOliver Dumpies
Oliver Dumpies
DODanilo Obradovic
Danilo Obradovic
JWJohannes Wilde
Johannes Wilde
FIfor the CHOICE-CLOSURE Investigators
for the CHOICE-CLOSURE Investigators
Background: Transcatheter aortic valve replacement is an established treatment option for patients with severe symptomatic aortic stenosis and is most commonly performed through the transfemoral access route. Percutaneous access site closure can be achieved using dedicated plug-based or suture-based vascular closure device (VCD) strategies, but randomized comparative studies are scarce. Methods: The CHOICE-CLOSURE trial (Randomized Comparison of Catheter-based Strategies for Interventional Access Site Closure during Transfemoral Transcatheter Aortic Valve Implantation) is an investigator-initiated, multicenter study, in which patients undergoing transfemoral transcatheter aortic valve replacement were randomly assigned to vascular access site closure using either a pure plug-based technique (MANTA, Teleflex) with no additional VCDs or a primary suture-based technique (ProGlide, Abbott Vascular) potentially complemented by a small plug. The primary end point consisted of access site– or access-related major and minor vascular complications during index hospitalization, defined according to the Valve Academic Research Consortium-2 criteria. Secondary end points included the rate of access site– or access-related bleeding, VCD failure, and time to hemostasis. Results: A total of 516 patients were included and randomly assigned. The mean age of the study population was 80.5±6.1 years, 55.4% were male, 7.6% of patients had peripheral vascular disease, and the mean Society of Thoracic Surgeons score was 4.1±2.9%. The primary end point occurred in 19.4% (50/258) of the pure plug-based group and 12.0% (31/258) of the primary suture-based group (relative risk, 1.61 [95% CI, 1.07–2.44], P =0.029). Access site– or access-related bleeding occurred in 11.6% versus 7.4% (relative risk, 1.58 [95%CI: 0.91–2.73], P =0.133) and device failure in 4.7% versus 5.4% (relative risk, 0.86, [95% CI, 0.40–1.82], P =0.841) in the respective groups. Time to hemostasis was significantly shorter in the pure plug-based group (80 [32–180] versus 240 [174–316] seconds, P <0.001). Conclusions: Among patients treated with transfemoral transcatheter aortic valve replacement, a pure plug-based vascular closure technique using the MANTA VCD is associated with a higher rate of access site– or access-related vascular complications but a shorter time to hemostasis compared with a primary suture-based technique using the ProGlide VCD. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT04459208.

4 March 2021 in Catheterization and Cardiovascular Interventions
Verified
Journal Article
Open access
PDF file
MKMitsunobu Kitamura
Mitsunobu Kitamura
NFNeil P. Fam
Neil P. Fam
DBDaniel Braun
Daniel Braun
TRTobias Ruf
Tobias Ruf
ASAtsushi Sugiura
Atsushi Sugiura
PLPhilipp Lurz
Philipp Lurz
Objectives: We investigated the durability of tricuspid regurgitation (TR) reduction and the clinical outcomes through 12 months after transcatheter tricuspid valve repair (TTVr) with the PASCAL Transcatheter Valve Repair System.Background: TTVr has rapidly developed and demonstrated favorable acute outcomes, but longer follow‐up data are needed.Methods: Overall, 30 patients (age 77 ± 6 years; 57% female) received PASCAL implantation from September 2017 to May 2019 and completed a clinical follow‐up at 12 months.Results: The TR etiology was functional in 25 patients (83%), degenerative in three (10%), and mixed in two (7%). All patients had TR severe or greater (massive or torrential in 80%) and heart failure symptoms (90% in NYHA III or IV) under optimal medical treatment. Single‐leaflet device attachment occurred in two patients. Moderate or less TR was achieved in 23/28 patients (82%) at 30 days, which was sustained at 12 months (86%). Two patients underwent repeat TTVr due to residual torrential TR (day 173) and recurrence of severe TR (day 280), respectively.One‐year survival rate was 93%; 6 patients required rehospitalization due to acute heart failure. NYHA functional class I or II was achieved in 90% and 6‐minute walk distance improved from 275 ± 122 m at baseline to 347 ± 112 m at 12‐month (+72 ± 82 m, p < .01). There was no stroke, endocarditis, or device embolization during the follow‐up.Conclusions: Twelve‐month outcomes from this multicenter compassionate use experience with the PASCAL System demonstrated high procedural success, acceptable safety, and significant clinical improvement.

7 November 2023 in Journal of the American Heart Association
Verified
Journal Article
Open access
RNRyo Nakamaru
Ryo Nakamaru
SKShun Kohsaka
Shun Kohsaka
YSYasuyuki Shiraishi
Yasuyuki Shiraishi
TKTakashi Kohno
Takashi Kohno
AGAyumi Goda
Ayumi Goda
TYTsutomu Yoshikawa
Tsutomu Yoshikawa
Background: The management of heart failure (HF) has markedly changed, due to changes in demographics and the emergence of novel pharmacotherapies. However, detailed analyses on the temporal trends in characteristics and outcomes among patients with HF are scarcely available. This study aimed to assess the temporal trends over 11 years in clinical management and outcomes in patients with HF. Methods and Results: We analyzed data from a multicenter registry of hospitalized patients with acute HF, including 6877 patients registered from 2011 to 2021. Age‐adjusted mortality was calculated using standardized mortality ratios. During the study period, mean age increased from 75.2 years in 2011 to 2012 to 76.4 years in 2020 to 2021 ( P for trend <0.001). The proportion of HF with reduced ejection fraction (HFrEF, left ventricular ejection fraction <40%) remained constant (from 43.4% to 42.7%, P for trend=0.38). The median duration of hospital stays (from 15 to 17 days, P for trend<0.001) had increased. As for the implementation of guideline‐directed medical therapy, the use of mineralocorticoid receptor antagonist at discharge increased in patients with HFrEF (from 44.3% to 60.2%, P for trend<0.001). There was also an increase in the use of sodium‐glucose cotransporter‐2 inhibitors following their approval for use. The age‐adjusted 1‐year mortality decreased in patients with HFrEF (from 18.0% to 9.3%, P for trend<0.001) but not in patients with non‐HFrEF (left ventricular ejection fraction ≥40%; from 9.2% to 9.5%, P for trend=0.79). Conclusions: Hospitalized patients with HF have been aging over the past decade. Their long‐term outcomes after discharge have improved predominantly because of decreased mortality in patients with HFrEF.

10 August 2018 in Clinical Research in Cardiology
Verified
Journal Article
Closed access
PDF file
MKMitsunobu Kitamura
Mitsunobu Kitamura
HKHidehiro Kaneko
Hidehiro Kaneko
MSMichael Schlüter
Michael Schlüter
DSDimitry Schewel
Dimitry Schewel
TSTobias Schmidt
Tobias Schmidt
CFChristian Frerker
Christian Frerker

1 September 2015 in The American Journal of Cardiology
Verified
Journal Article
Open access
MKMitsunobu Kitamura
Mitsunobu Kitamura
MTMorimasa Takayama
Morimasa Takayama
JMJunya Matsuda
Junya Matsuda
YKYoshiaki Kubota
Yoshiaki Kubota
SNShunichi Nakamura
Shunichi Nakamura
WSWataru Shimizu
Wataru Shimizu
Careful evaluation, including provocation tests, is needed to specify an indication for septal reduction therapy in patients with drug-refractory hypertrophic obstructive cardiomyopathy. This study aimed to evaluate the outcome of alcohol septal ablation (ASA) using an intravenous nitroglycerin test (IV-NTG). Of consecutive 156 patients, after excluding cases of severe valvular disease and repeat septal reduction therapy, we investigated the clinical characteristics of patients with labile obstruction (n = 32) and the outcomes after ASA using the IV-NTG test; comparisons were made with those exhibiting basal obstruction (a resting gradient of ≥30 mm Hg). The patients with labile obstruction had less left ventricular mass (141 ± 47 vs 182 ± 59 g, p = 0.003) and less brain natriuretic peptide values (414 ± 576 vs 744 ± 625 pg/ml, p <0.001) than those with basal obstruction. Immediately after ASA, the gradients improved from 15 ± 7 to 5 ± 5 mm Hg and the IV-NTG-provoked gradients improved from 74 ± 25 to 13 ± 9 mm Hg, respectively. At 1-year follow-up, the New York Heart Association functional class had improved from 2.7 ± 0.5 to 1.3 ± 0.5. There was no sudden cardiac death during the follow-up period (5.1 ± 3.0 years), and 8-year survival free from cardiovascular death was 94%. In conclusion, patients with labile obstruction had less-severe left ventricular hypertrophy but exhibited symptoms comparable to those with basal obstruction. The IV-NTG test is a useful method for rapidly confirming acute reduction of the latent gradient after the ASA procedure, and the outcome of ASA for labile obstruction was favorable.